Extranodal NK-T-cell lymphoma differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
(5 intermediate revisions by 2 users not shown) | |||
Line 7: | Line 7: | ||
Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from [[Wegener's granulomatosis|Wegner's granulomatosis]], [[Polymorphic]] reticulosis, and Midline malignant [[Lymphomas|lymphoma]] | Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from [[Wegener's granulomatosis|Wegner's granulomatosis]], [[Polymorphic]] reticulosis, and Midline malignant [[Lymphomas|lymphoma]] | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.<ref name="KarubeAoki2008">{{cite journal|last1=Karube|first1=Kennosuke|last2=Aoki|first2=Ryosuke|last3=Nomura|first3=Yuko|last4=Yamamoto|first4=Kohei|last5=Shimizu|first5=Kay|last6=Yoshida|first6=Shirou|last7=Komatani|first7=Hideki|last8=Sugita|first8=Yasuo|last9=Ohshima|first9=Koichi|title=Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases|journal=Pathology International|volume=58|issue=2|year=2008|pages=89–97|issn=13205463|doi=10.1111/j.1440-1827.2007.02195.x}}</ref> | *Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.<ref name="KarubeAoki2008">{{cite journal|last1=Karube|first1=Kennosuke|last2=Aoki|first2=Ryosuke|last3=Nomura|first3=Yuko|last4=Yamamoto|first4=Kohei|last5=Shimizu|first5=Kay|last6=Yoshida|first6=Shirou|last7=Komatani|first7=Hideki|last8=Sugita|first8=Yasuo|last9=Ohshima|first9=Koichi|title=Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases|journal=Pathology International|volume=58|issue=2|year=2008|pages=89–97|issn=13205463|doi=10.1111/j.1440-1827.2007.02195.x}}</ref> | ||
Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as:<ref name="Hindawi">Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016 </ref> | *Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as:<ref name="Hindawi">Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016 </ref><ref name="pmid58185232">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523 }}</ref> | ||
**[[NK cell lukemia]] | |||
**[[Lymphomatoid granulomatosis]] | |||
**[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]] | |||
**[[Anaplastic large cell lymphoma]] | |||
**Non specific inflammatory process | |||
**[[Enteropathy associated T cell lymphoma]] | |||
**[[Peripheral T cell lymphoma]] | |||
**[[Hepatosplenic T cell lymphoma]] | |||
* | *Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:<ref name="pmid5818523">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523 }}</ref> | ||
**[[Wegener's granulomatosis|Wegner's granulomatosis]] | |||
**[[Polymorphic]] reticulosis | |||
**Midline malignant [[Lymphomas|lymphoma]] | |||
Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:<ref name="pmid5818523">{{cite journal| author=Kassel SH, Echevarria RA, Guzzo FP| title=Midline malignant reticulosis (so-called lethal midline granuloma). | journal=Cancer | year= 1969 | volume= 23 | issue= 4 | pages= 920-35 | pmid=5818523 | doi=10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5818523 }}</ref> | |||
* [[Wegener's granulomatosis|Wegner's granulomatosis]] | |||
* [[Polymorphic]] reticulosis | |||
* Midline malignant [[Lymphomas|lymphoma]] | |||
=== Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection: === | === Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection: === | ||
Extranodal NK T-cell lymphoma express [[CD56]] on its surface accompanied with [[EBV]] infection. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width:600px" | {| style="border: 0px; font-size: 90%; margin: 3px; width:600px" | ||
| valign="top" | | | valign="top" | | ||
|+ | |+ | ||
'''Malignancies based on immunophenotype and EBV infection''' | '''Malignancies based on immunophenotype and EBV infection''' | ||
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Disease}} | ! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|Disease}} | ||
!style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF| | ! style="background: #4479BA; width: 250px;" |{{fontcolor|#FFF|Immunophenotype}} | ||
!style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|EBV}} | ! style="background: #4479BA; width: 100px;" |{{fontcolor|#FFF|EBV}} | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[NK cell leukemia]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[NK cell leukemia]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD16+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD16]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Lymphomatoid granulomatosis]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Lymphomatoid granulomatosis]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Diffuse large B cell lymphoma|EBV-positive diffuse large B cell lymphoma, NOS]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD20+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD20]]+ [[CD76]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | + | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Peripheral T cell lymphoma|Peripheral T cell lymphoma, unspecified]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD3+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD3 (immunology)|CD3]]+ [[CD56]]- | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Anaplastic large cell lymphoma, ALK positive|Anaplastic large cell lymphoma]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD30+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD30]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|- | |- | ||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center"|[[Hepatosplenic T cell lymphoma]] | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |[[Hepatosplenic T cell lymphoma]] | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |CD2+ | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" |[[CD2]]+ [[CD70|CD7]]+ [[CD3 (immunology)|CD3]]+ | ||
|style="padding: 5px 5px; background: #F5F5F5; align="center" |- | | style="padding: 5px 5px; background: #F5F5F5; font-weight: bold" align="center" | - | ||
|} | |} | ||
Latest revision as of 15:25, 16 September 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2] Sowminya Arikapudi, M.B,B.S. [3]
Overview
Extranodal NK-T-cell lymphoma must be differentiated from other diseases such as NK cell lukemia, lymphomatoid granulomatosis, EBV-positive diffuse large B cell lymphoma, NOS, anaplastic large cell lymphoma, non specific inflammatory process, enteropathy associated T cell lymphoma, peripheral T cell lymphoma, hepatosplenic T cell lymphoma
Extranodal NK/T-cell lymphoma, nasal type must be diffrentiated from Wegner's granulomatosis, Polymorphic reticulosis, and Midline malignant lymphoma
Differential Diagnosis
- Extranodal NK t-cell must be differentiated with other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoprolifrative disorders.[1]
- Extranodal NK-T cell lymphoma, nasal type shows aggresive lethal midline granuloma macroscopicaly so it must be differentiated from diseases such as:[4]
- Wegner's granulomatosis
- Polymorphic reticulosis
- Midline malignant lymphoma
Differentiating extranodal NK T-cell from other hematologic malignancies by immunophenotype and EBV infection:
Extranodal NK T-cell lymphoma express CD56 on its surface accompanied with EBV infection.
Disease | Immunophenotype | EBV |
---|---|---|
NK cell leukemia | CD16+ | + |
Lymphomatoid granulomatosis | CD20+ | + |
EBV-positive diffuse large B cell lymphoma, NOS | CD20+ CD76+ | + |
Peripheral T cell lymphoma, unspecified | CD3+ CD56- | - |
Anaplastic large cell lymphoma | CD30+ | - |
Hepatosplenic T cell lymphoma | CD2+ CD7+ CD3+ | - |
References
- ↑ Karube, Kennosuke; Aoki, Ryosuke; Nomura, Yuko; Yamamoto, Kohei; Shimizu, Kay; Yoshida, Shirou; Komatani, Hideki; Sugita, Yasuo; Ohshima, Koichi (2008). "Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: Analysis of 490 cases". Pathology International. 58 (2): 89–97. doi:10.1111/j.1440-1827.2007.02195.x. ISSN 1320-5463.
- ↑ Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. Hindawi Publishing Corporation. http://www.hindawi.com/journals/ah/2010/627401/. Accessed on February 19, 2016
- ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.
- ↑ Kassel SH, Echevarria RA, Guzzo FP (1969). "Midline malignant reticulosis (so-called lethal midline granuloma)". Cancer. 23 (4): 920–35. doi:10.1002/1097-0142(196904)23:4<920::aid-cncr2820230430>3.0.co;2-m. PMID 5818523.